MiCo BioMed Co., Ltd. (KOSDAQ:214610)
South Korea
· Delayed Price · Currency is KRW 527.00
-22.00 (-4.01%)
At close: Mar 25, 2025, 3:30 PM KST
MiCo BioMed Revenue
MiCo BioMed had revenue of 2.48B KRW in the quarter ending September 30, 2024, with 76.25% growth. This brings the company's revenue in the last twelve months to 8.30B, up 61.39% year-over-year. In the year 2023, MiCo BioMed had annual revenue of 5.37B, down -66.69%.
Revenue (ttm)
8.30B
Revenue Growth
+61.39%
P/S Ratio
2.61
Revenue / Employee
116.94M
Employees
71
Market Cap
27.24B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 5.37B | -10.74B | -66.69% |
| Dec 31, 2022 | 16.11B | -14.19B | -46.83% |
| Dec 31, 2021 | 30.30B | -15.37B | -33.65% |
| Dec 31, 2020 | 45.67B | 41.57B | 1,014.47% |
| Dec 31, 2019 | 4.10B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Electronics | 300.87T |
| SK hynix | 66.19T |
| LG Energy Solution | 25.62T |
| Samsung Biologics | 4,547.32B |
| Hyundai Motor Company | 175.23T |
| Celltrion | 3,557.30B |
| Kia Corporation | 107.45T |
| KB Financial Group | 15.01T |